Back in April 2024, I assigned Day One Biopharmaceuticals, Inc. (DAWN) stock a "Hold" rating in a note for the Seeking Alpha, covering the news that its lead asset tovorafenib had been awarded an ...
Xbox Game Pass users are divided over a new day-one game from a legendary developer. The new day-one game is actually an Xbox ...
Day One Biopharmaceuticals has announced the appointment of Dr. Michael Vasconcelles as Head of Research & Development, bringing over 25 years of experience in oncology research and corporate ...
Day One Biopharmaceuticals (DAWN) has signed a definitive merger agreement to acquire clinical-stage biopharmaceutical company Mersana Therapeutics (MRSN) in a deal value of up to around $285 million.
Acquisition expands Day One’s pipeline with clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) targeting rare cancer adenoid cystic carcinoma (ACC) BRISBANE, Calif., Jan. 06, ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — The French pharma company Servier said Friday that it would buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results